A Phase 2 study of retreating with osimertinib after chemotherapy in EGFR+ lung cancer
Recruiting Phase 2 NCT04335292
Study Description
Evaluating the safety and effectiveness of retreating with osimertinib after chemotherapy in EGFR-mutated advanced lung cancer
Study Details
- Registry ID:
- NCT04335292
- Conditions:
- Non-Small Cell Lung Cancer
- Phase:
- Phase 2
- Target Enrollment:
- 200 participants
- Start Date:
- Healthy Volunteers:
- No
Study Locations (10 sites)
-
The Ottawa Hospital
Ottawa, Ontario, Canada -
Durham Regional Cancer Centre, Lakeridge Health
Oshawa, Ontario, Canada -
Sunnybrook Research Institute
Toronto, Ontario, Canada -
Princess Margaret Hospital
Toronto, Ontario, Canada -
Hamilton Health Sciences Centre, Juravinski Cancer Centre
Hamilton, Ontario, Canada -
William Osler Health System
Brampton, Ontario, Canada -
Grand River Regional Cancer Centre
Kitchener, Ontario, Canada -
London Regional Cancer Program of the Lawson Health Research Institute
London, Ontario, Canada -
BC Cancer Agency
Vancouver, British Columbia, Canada -
Lions Gate Hospital
Vancouver, British Columbia, Canada
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.